缺血修饰白蛋白对急性冠脉综合征短期及长期预后的临床价值

Clinical value of ischaemic modified albumin in short term and long-term prognosis of acute coronary syndrome

目前,急性冠脉综合征(ACS)发病率及死亡率日益增加,发病年龄逐渐年轻化,经典诊断标志物有肌红蛋白、肌钙蛋白、肌酸激酶和肌酸激酶同工酶质量。血清缺血修饰白蛋白(IMA)为近几年热门的心肌缺血标志物,被用于ACS的早期诊断、危险分层及指导治疗方面。对于IMA的研究,多侧重于对ACS的早期诊断,但对于ACS的短期及长期预后仍不可忽视,针对IMA的ACS患者与预后的关系研究较少,本文旨在对血清IMA水平与急性冠脉综合征患者的预后相关性作一综述。

At present,the incidence and mortality of acute coronary syndrome(ACS)are increasing,and the age of onset is getting younger.The classic diagnostic markers are myoglobin,troponin,creatine kinase and creatine kinase isoenzyme quality.The ischemia modified albumin(IMA)is popular myocardial ischemia marker in recent years,and it is used in the early diagnosis,risk stratification and treatment of ACS.Research on IMA focuses on the early diagnosis of ACS,but the short-term and long-term prognosis of ACS cannot be ignored.However,there are few studies on the relationship between ACS patients and prognosis of IMA,this article will focus on the relationship between IMA and the prognostic relevance of ACS is further explored.